Halozyme Therapeutics EBIT 2010-2024 | HALO

Halozyme Therapeutics EBIT for the quarter ending September 30, 2024 was $0.163B, a 84.87% increase year-over-year.

  • Halozyme Therapeutics 2023 EBIT was 0.338B, a 26.18% increase from 2022.
  • Halozyme Therapeutics 2022 EBIT was 0.268B, a 3.03% decline from 2021.
  • Halozyme Therapeutics 2021 EBIT was 0.276B, a 91.26% increase from 2020.

EBIT can be defined as earnings before interest and taxes.

Halozyme Therapeutics EBIT 2010-2024 | HALO

  • Halozyme Therapeutics 2023 EBIT was 0.338B, a 26.18% increase from 2022.
  • Halozyme Therapeutics 2022 EBIT was 0.268B, a 3.03% decline from 2021.
  • Halozyme Therapeutics 2021 EBIT was 0.276B, a 91.26% increase from 2020.

EBIT can be defined as earnings before interest and taxes.